These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

623 related items for PubMed ID: 19502270

  • 1. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I, Sala R, Bazzani C, Ceribelli A, Zane C, Cattaneo R, Tincani A, Calzavara-Pinton PG, Franceschini F.
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [Abstract] [Full Text] [Related]

  • 2. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM.
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [Abstract] [Full Text] [Related]

  • 3. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
    Momose Y, Arai S, Eto H, Kishimoto M, Okada M.
    J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
    [Abstract] [Full Text] [Related]

  • 4. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A, Porta S, Ríos R, Martinez-Zapico A, Ortego-Centeno N, Agesta N, Ruiz-Irastorza G.
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [Abstract] [Full Text] [Related]

  • 5. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
    Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T.
    Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
    [Abstract] [Full Text] [Related]

  • 6. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y.
    Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
    [Abstract] [Full Text] [Related]

  • 7. Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
    Zeidi M, Kim HJ, Werth VP.
    J Invest Dermatol; 2019 Feb; 139(2):324-332. PubMed ID: 30227141
    [Abstract] [Full Text] [Related]

  • 8. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative.
    Lampropoulos CE, Sangle S, Harrison P, Hughes GR, D'Cruz DP.
    Rheumatology (Oxford); 2004 Nov; 43(11):1383-5. PubMed ID: 15266063
    [Abstract] [Full Text] [Related]

  • 9. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
    Francès C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, Bessis D, Chevrant-Breton J, Cordel N, Lipsker D, Costedoat-Chalumeau N.
    Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
    [Abstract] [Full Text] [Related]

  • 10. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
    González-Sixto B, García-Doval I, Oliveira R, Posada C, García-Cruz MA, Cruces M.
    Actas Dermosifiliogr; 2010 Apr; 101(1):54-8. PubMed ID: 20109393
    [Abstract] [Full Text] [Related]

  • 11. [Classification of dermatologic manifestations in lupus erythematosus].
    Francès C, Barete S, Ayoub N, Piette JC.
    Ann Med Interne (Paris); 2003 Feb; 154(1):33-44. PubMed ID: 12746657
    [Abstract] [Full Text] [Related]

  • 12. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.
    Costedoat-Chalumeau N, Amoura Z, Hulot JS, Aymard G, Leroux G, Marra D, Lechat P, Piette JC.
    Ann Rheum Dis; 2007 Jun; 66(6):821-4. PubMed ID: 17324970
    [Abstract] [Full Text] [Related]

  • 13. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
    Feldmann R, Salomon D, Saurat JH.
    Dermatology; 1994 Jun; 189(4):425-7. PubMed ID: 7873836
    [Abstract] [Full Text] [Related]

  • 14. Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus.
    Raptopoulou A, Linardakis C, Sidiropoulos P, Kritikos HD, Boumpas DT.
    Lupus; 2010 May; 19(6):744-7. PubMed ID: 20179172
    [Abstract] [Full Text] [Related]

  • 15. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.
    Carmichael SJ, Day RO, Tett SE.
    Intern Med J; 2013 May; 43(5):547-53. PubMed ID: 23425382
    [Abstract] [Full Text] [Related]

  • 16. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.
    Costedoat-Chalumeau N, Amoura Z, Huong DL, Lechat P, Piette JC.
    Autoimmun Rev; 2005 Feb; 4(2):111-5. PubMed ID: 15722258
    [Abstract] [Full Text] [Related]

  • 17. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group.
    Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DL, Sebbough D, Wechsler B, Vauthier D, Denjoy I, Lupoglazoff JM, Piette JC.
    Arthritis Rheum; 2003 Nov; 48(11):3207-11. PubMed ID: 14613284
    [Abstract] [Full Text] [Related]

  • 18. Hydroxychloroquine in lupus pregnancy.
    Clowse ME, Magder L, Witter F, Petri M.
    Arthritis Rheum; 2006 Nov; 54(11):3640-7. PubMed ID: 17075810
    [Abstract] [Full Text] [Related]

  • 19. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L, Zhang L, Feng R, Werth VP.
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [Abstract] [Full Text] [Related]

  • 20. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
    Ang GC, Werth VP.
    Arch Dermatol; 2005 Jul; 141(7):855-9. PubMed ID: 16027300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.